---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-053109"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2023-10-12T23:59:59+00:00"
generated_at: "2026-06-10T00:54:43.112919+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics reports RLY-4008 data: 35% ORR in FGFR2 fusions; cash runway extended to 2H2026

## Summary
- RLY-4008 achieved 35% ORR in FGFR2-fusion tumors (n=26) and 40% ORR in HR+/HER2- breast cancer (n=10); durable responses of ≥6 months in most responders.
- In FGFR2-amplified tumors, 24% ORR (8/34) across multiple tumor types; early signals in FGFR2 mutations (3 PRs).
- Safety profile consistent with prior data: no Grade 4/5 adverse events; off-target toxicities clinically insignificant.
- Pipeline update: plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet by YE 2023; pause RLY-2139 (CDK2 inhibitor) development.
- Cash runway extended by ~1 year, now sufficient into 2H2026; CCA commercial readiness paused to focus on tumor-agnostic opportunity.

## SEC filing metadata
- accession: 0000950170-23-053109
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2023-10-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017023053109/0000950170-23-053109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017023053109/rlay-20231012.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-053109
- JSON: https://secwatch.observer/filing/0000950170-23-053109.json
- Plain text: https://secwatch.observer/filing/0000950170-23-053109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.